Besvil Trio 200 in Asthma

Before we begin, please tell us about yourself

Start Survey

1. What proportion of your asthma patients remain uncontrolled on ICS/LABA therapy?

<10% 10–25% 26–50% >50%

2. What percentage of your asthma patients require triple inhaler therapy?

<20% 20–40% 40–60% >60% Other

3. When do you typically escalate patients to triple therapy?

Uncontrolled on medium-dose ICS/LABA Uncontrolled on high-dose ICS/LABA After ≥2 exacerbations At a later stage of disease progression

4. What is the primary reason for escalating asthma therapy?

Poor symptom control Frequent exacerbations Night-time symptoms Reduced lung function

5. Which triple therapy combination do you prescribe most frequently for uncontrolled asthma patients?

Budesonide + Formoterol + Glycopyrronium Vilanterol + Umeclidinium + Fluticasone Budesonide + Formoterol + Tiotropium (MITT) Indacaterol + Glycopyrronium + Mometasone Other

6. What key attribute influences your decision to prescribe the following triple therapies in asthma?

7. Which attribute would most encourage you to prescribe Besvil Trio 200?

Better symptom control Lower exacerbation risk Single-inhaler convenience Better value for money

8. What percentage of your asthma patients would you prefer to treat with each therapy? (Total = 100%)

9. In which uncontrolled asthma patient profile would you be most likely to initiate Vilanterol + Umeclidinium + Fluticasone 200?

Frequent daytime and night-time symptoms ≥2 exacerbations in the past year Persistent airflow limitation despite ICS/LABA All of the above

10. What percentage of your current SITT prescriptions are Vilanterol + Umeclidinium + Fluticasone?

<10% 10–25% 26–50% >50%

11. What is the biggest barrier to prescribing Vilanterol + Umeclidinium + Fluticasone more frequently?

12. What factors limit the use of Vilanterol + Umeclidinium + Fluticasone in certain asthma patients compared with other SITTs?